With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies
When Adrian Woolfson was head of R&D at Sangamo, he began contemplating starting his own company. His goal? Solve some of the key challenges plaguing genomic medicine he’d seen while working on a wide spectrum of Sangamo’s programs.
Then, he met Lachlan MacKinnon, a biotech investor, in London, and the two realized they shared a similar vision, despite their “orthogonal” backgrounds, he told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.